Effect of metformin on the level of anti-Mullerian hormone in therapy of polycystic ovary syndrome in obese women

Minerva Ginecol. 2014 Feb;66(1):85-9.

Abstract

Aim: Anti-Mullerian hormone (AMG) reduction in women with hyperinsulinemia in therapy with metformin suggests that metformin affects the level of AMH and ovulatory dysfunction through insulin-mediated mechanisms. Aim of the study was to assess the effects of metformin hydrochloride (Siofor) on the level of AMH in women with polycystic ovary syndrome and obesity.

Methods: The study involved 40 women with PCOS, aged 22 to 35 years (mean age 28.7±5.2 years) with body mass index (BMI) 32.5±4.3 kg/m2. All patients received metformin hydrochloride (Siofor) orally, 1 tablet (850 mg) two times a day for six months. After three and six months of therapy anthropometric characteristics, concentration of hormones in the blood serum were assessed.

Results: In patients receiving Siofor a decrease of BMI, waist-hip ratio (P<0.05), concentration of T, as well as free androgen index (FAI) (P<0.01) was shown. Furthermore, there was a decrease in ovarian volume by 12%. AMH concentration during therapy did not changed significantly.

Conclusion: The hypothesis that a decline in AMG level is a consequence of the reduced BMI, which was significant in the group of women with hyperinsulinemia, does not seem convincing in view of the fact that patients with a normal insulin level also showed a trend to lower BMI, which, however, was not accompanied by a decrease in its concentration.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Anti-Mullerian Hormone / blood*
  • Body Mass Index
  • Female
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Insulin / metabolism
  • Metformin / pharmacology*
  • Obesity / physiopathology*
  • Polycystic Ovary Syndrome / drug therapy*
  • Polycystic Ovary Syndrome / physiopathology
  • Time Factors
  • Young Adult

Substances

  • Hypoglycemic Agents
  • Insulin
  • Anti-Mullerian Hormone
  • Metformin